Cardiovascular Drugs Practice Questions

Q: A 50-year-old male with hyperlipidemia is prescribed a statin. What is the primary mechanism of action of statins?

Inhibition of HMG-CoA reductase. ***Inhibition of HMG-CoA reductase*** - Statins primarily act by inhibiting **3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase**, a key enzyme in the cholesterol synthesis pathway in the liver. - This inhibition leads to a decrease in **hepatic cholesterol production**, which in turn upregulates LDL receptors on liver cells, increasing the clearance of LDL from the blood. *Inhibition of cholesterol absorption* - This mechanism is characteristic of drugs like **ezetimibe**, which specifically block the **Niemann-Pick C1-like 1 (NPC1L1)** protein in the small intestine. - While it lowers cholesterol, it is not the primary action of statins. *Stimulation of lipoprotein lipase* - **Lipoprotein lipase (LPL)** activity primarily enhances the clearance of **triglyceride-rich lipoproteins** from the circulation. - Fibrates, for example, increase LPL activity, whereas statins exert their main effect through cholesterol synthesis inhibition. *Inhibition of bile acid reabsorption* - This mechanism is associated with **bile acid sequestrants** (e.g., cholestyramine), which bind to bile acids in the intestine, preventing their reabsorption and increasing their fecal excretion. - This forces the liver to use more cholesterol to synthesize new bile acids, thereby lowering serum cholesterol, but it is not a statin's mechanism.

Q: A patient with pulmonary arterial hypertension is prescribed a phosphodiesterase-5 inhibitor to improve exercise capacity and reduce symptoms. Which of the following drugs is most likely to be prescribed?

Sildenafil. **Sildenafil** - **Sildenafil** is a **phosphodiesterase-5 (PDE5) inhibitor** commonly used to treat pulmonary arterial hypertension (PAH) by promoting vasodilation in the pulmonary arteries. - It works by increasing levels of **cyclic guanosine monophosphate (cGMP)**, leading to relaxation of pulmonary vascular smooth muscle, improving exercise capacity, and reducing symptoms. *Bosentan* - **Bosentan** is an **endothelin receptor antagonist**, not a PDE5 inhibitor, and primarily acts by blocking the effects of endothelin-1, a potent vasoconstrictor. - While used in PAH, its mechanism of action is distinct from the requested drug class. *Epoprostenol* - **Epoprostenol** is a synthetic **prostacyclin analogue** that functions as a potent vasodilator and inhibitor of platelet aggregation. - It is administered intravenously and is used in severe PAH, but it is not a PDE5 inhibitor. *Iloprost* - **Iloprost** is also a **prostacyclin analogue**, similar to epoprostenol, and causes vasodilation and anti-platelet effects. - It is typically administered via inhalation but does not belong to the PDE5 inhibitor class.

Q: A patient with chronic atrial fibrillation is on digoxin. What is the primary mechanism of action of digoxin?

Inhibition of Na+/K+ ATPase. ***Inhibition of Na+/K+ ATPase*** - Digoxin directly inhibits the **Na+/K+ ATPase pump** in cardiac myocytes, leading to increased intracellular sodium [1]. - This increased sodium then reduces the activity of the **Na+/Ca2+ exchanger**, resulting in increased intracellular calcium and enhanced myocardial contractility [3]. *Beta-blockade* - Beta-blockers primarily reduce heart rate and contractility by blocking the effects of **norepinephrine** and **epinephrine** at beta-adrenergic receptors [2]. - Digoxin does not exert its primary therapeutic effects through this mechanism. *Calcium channel blockade* - Calcium channel blockers typically reduce the influx of **calcium ions** into cardiac and smooth muscle cells, leading to decreased contractility and vasodilation. - Digoxin, conversely, increases intracellular calcium to enhance contractility [3]. *Alpha-adrenergic blockade* - Alpha-adrenergic blockers primarily cause **vasodilation** by blocking alpha-receptors, leading to reduced blood pressure. - This mechanism is not relevant to digoxin's therapeutic actions on cardiac rhythm or contractility.

Q: A heart failure patient is treated with an ACE inhibitor. How does this medication influence renal sodium excretion?

Decreases angiotensin II, leading to Na+ excretion. ***Decreases angiotensin II, leading to Na+ excretion*** - ACE inhibitors block the conversion of angiotensin I to **angiotensin II**. Angiotensin II normally promotes sodium reabsorption in the renal tubules and stimulates **aldosterone** release. - By reducing angiotensin II levels, ACE inhibitors lead to **decreased sodium reabsorption** and increased sodium excretion, which helps reduce fluid volume in heart failure. *Decreases angiotensin II, leading to Na+ retention* - While ACE inhibitors do decrease angiotensin II, this effect **reduces sodium reabsorption**, leading to excretion, not retention. - **Sodium retention** would worsen heart failure symptoms due to increased fluid volume. *Increases aldosterone, leading to Na+ retention* - ACE inhibitors actually **decrease aldosterone** secretion, as angiotensin II is a primary stimulus for aldosterone release. - Reduced aldosterone leads to **decreased sodium reabsorption** and potassium excretion. *Increases angiotensin II, leading to Na+ excretion* - ACE inhibitors work by **decreasing**, not increasing, **angiotensin II levels**. - While increased Na+ excretion is the correct outcome, the premise of increased angiotensin II is **incorrect** regarding the mechanism of ACE inhibitors.

Q: What is the primary direct effect of a beta-blocker on cardiac function?

Decrease heart rate. ***Decrease heart rate*** - Beta-blockers primarily antagonize **beta-1 adrenergic receptors** in the heart, leading to reduced sympathetic stimulation. - This antagonism results in **slowing of the sinoatrial (SA) node firing rate**, which directly decreases the heart rate (negative chronotropy). - This is the **most direct and primary pharmacological effect** on cardiac function. *Increase contractility* - Beta-blockers **reduce cardiac contractility** (negative inotropy), not increase it, by blocking beta-1 receptors which are responsible for increasing intracellular calcium and enhancing contraction. - An increase in contractility would be an effect of **beta-agonists** (e.g., dobutamine) or other positive inotropic agents. *Increase heart rate* - Beta-blockers are designed to **decrease heart rate**, not increase it, by blocking the effects of norepinephrine and epinephrine on beta-1 receptors in the SA node. - An increased heart rate is typically seen with **sympathetic activation** or administration of chronotropic agents like atropine. *Decrease myocardial oxygen demand* - While beta-blockers do decrease myocardial oxygen demand, this is a **secondary therapeutic benefit** resulting from their primary actions of reducing heart rate, contractility, and blood pressure. - This is clinically important (especially in angina and MI), but the **primary direct pharmacological effect** is the decrease in heart rate through SA node inhibition.

Q: A patient treated for hypertension shows signs of hyperkalemia. Which class of antihypertensive agents is most likely to cause this side effect?

ACE inhibitors. ***ACE inhibitors*** - **Angiotensin-converting enzyme (ACE) inhibitors** block the conversion of angiotensin I to angiotensin II, leading to decreased aldosterone secretion. - Reduced **aldosterone** levels decrease sodium reabsorption and potassium excretion in the renal tubules, resulting in **hyperkalemia**. *Calcium channel blockers* - **Calcium channel blockers** primarily work by causing vasodilation and reducing myocardial contractility. - They typically do not directly affect potassium levels and are not associated with **hyperkalemia**. *Beta-blockers* - **Beta-blockers** reduce heart rate and cardiac output by blocking beta-adrenergic receptors. - While they can cause slight shifts in potassium distribution, they are not a common cause of significant **hyperkalemia**. *Thiazide diuretics* - **Thiazide diuretics** inhibit sodium and chloride reabsorption in the distal convoluted tubule. - This promotes increased potassium excretion, leading to **hypokalemia**, not hyperkalemia.

Q: A 62-year-old patient with unstable angina is prescribed a drug to reduce myocardial oxygen demand. Which drug would be the best option?

Metoprolol. ***Metoprolol*** - As a **beta-blocker**, metoprolol **decreases heart rate** and **myocardial contractility**, thereby reducing **myocardial oxygen demand**. - This reduction in demand is crucial for managing unstable angina, where the oxygen supply is insufficient to meet demand. *Rivaroxaban* - Rivaroxaban is an **anticoagulant** that works by inhibiting Factor Xa, and its primary role is to prevent **thromboembolic events**, not to directly reduce myocardial oxygen demand. - While it may be used in coronary artery disease to prevent clot formation, it does not directly manage the **angina symptoms** by affecting heart rate or contractility. *Rosuvastatin* - Rosuvastatin is a **statin**, used to lower **cholesterol levels** and stabilize **atherosclerotic plaques**. - Its main function is to **prevent the progression of atherosclerosis** and reduce the risk of future cardiovascular events, not to acutely reduce myocardial oxygen demand for angina relief. *Captopril* - Captopril is an **ACE inhibitor** that primarily works by causing **vasodilation** and reducing **blood pressure**, which can decrease afterload and indirectly reduce myocardial oxygen demand. - However, **beta-blockers** like metoprolol are more direct and effective at reducing oxygen demand by significantly lowering heart rate and contractility, making them the preferred first-line treatment for this indication.

Q: What is the primary concern regarding the dosing of statins in patients with hepatic impairment?

Increased risk of toxicity due to reduced clearance. Increased risk of toxicity due to reduced clearance - Hepatic impairment significantly reduces the liver's ability to metabolize and clear statins from the body - This reduced clearance results in higher systemic exposure to the drug, increasing the risk of dose-dependent adverse effects such as myopathy and rhabdomyolysis [1] - The primary clinical concern is the increased toxicity risk, which necessitates careful dose adjustment and monitoring Potential for reduced efficacy due to altered metabolism - While metabolism may be altered, the primary concern is increased drug levels rather than reduced efficacy [2] - Most statins are metabolized to active or inactive metabolites, and hepatic impairment typically increases rather than decreases drug exposure [2] - Reduced efficacy is uncommon unless severe hepatic dysfunction prevents conversion of prodrug statins Need for mandatory dose reduction in all cases regardless of severity - Dose adjustment is not automatically required in all cases of hepatic impairment - Management depends on the severity of hepatic dysfunction (Child-Pugh class) and the specific statin used - Some statins (e.g., rosuvastatin, pravastatin) undergo minimal hepatic metabolism and may be safer options - The concern is toxicity risk, not blanket dose reduction Altered bioavailability due to first-pass metabolism - While first-pass metabolism can be altered in hepatic impairment, this typically results in increased bioavailability for highly extracted drugs [2] - Increased bioavailability would contribute to higher systemic exposure and toxicity, not a separate primary concern - The core issue remains overall drug accumulation and toxicity risk [1]

Q: Which antihypertensive drug works by inhibiting the angiotensin-converting enzyme and reducing the production of angiotensin II?

Enalapril. ***Enalapril*** - **Enalapril** is an **ACE inhibitor** that specifically blocks the conversion of **angiotensin I** to **angiotensin II**, thereby reducing blood pressure. - This action leads to **vasodilation**, reduced **aldosterone secretion**, and decreased **sodium and water retention**. *Losartan* - **Losartan** is an **angiotensin receptor blocker (ARB)**, which works by *blocking* the binding of **angiotensin II** to its receptors, rather than inhibiting its production. - While it also reduces the effects of **angiotensin II**, its mechanism of action is distinct from **ACE inhibitors**. *Amlodipine* - **Amlodipine** is a **calcium channel blocker** that primarily causes **vasodilation** by inhibiting calcium influx into vascular smooth muscle cells. - It does not directly interact with the **renin-angiotensin-aldosterone system (RAAS)**. *Hydralazine* - **Hydralazine** is a **direct vasodilator** that acts primarily on arterial smooth muscle to cause relaxation, leading to a reduction in **peripheral vascular resistance**. - Its mechanism is independent of the **RAAS** and does not involve **angiotensin-converting enzyme**.

Question 1

A 50-year-old male with hyperlipidemia is prescribed a statin. What is the primary mechanism of action of statins?

Accepted Answer

Inhibition of HMG-CoA reductase

Answer

Inhibition of cholesterol absorption

Answer

Stimulation of lipoprotein lipase

Answer

Inhibition of bile acid reabsorption

Question 2

A patient with pulmonary arterial hypertension is prescribed a phosphodiesterase-5 inhibitor to improve exercise capacity and reduce symptoms. Which of the following drugs is most likely to be prescribed?

Accepted Answer

Sildenafil

Answer

Bosentan

Answer

Epoprostenol

Answer

Iloprost

Question 3

A patient with hypercholesterolemia has a mutation in the LDL receptor gene. Evaluate the potential effect of statin therapy in this patient.

Accepted Answer

Increased LDL receptor expression, reduced cholesterol synthesis

Answer

Decreased LDL receptor expression, increased cholesterol synthesis

Answer

Increased LDL receptor expression, increased cholesterol synthesis

Answer

Decreased LDL receptor expression, reduced cholesterol synthesis

Question 4

A patient with chronic atrial fibrillation is on digoxin. What is the primary mechanism of action of digoxin?

Accepted Answer

Inhibition of Na+/K+ ATPase

Answer

Beta-blockade

Answer

Calcium channel blockade

Answer

Alpha-adrenergic blockade

Question 5

A heart failure patient is treated with an ACE inhibitor. How does this medication influence renal sodium excretion?

Accepted Answer

Decreases angiotensin II, leading to Na+ excretion

Answer

Decreases angiotensin II, leading to Na+ retention

Answer

Increases aldosterone, leading to Na+ retention

Answer

Increases angiotensin II, leading to Na+ excretion

Question 6

What is the primary direct effect of a beta-blocker on cardiac function?

Accepted Answer

Decrease heart rate

Answer

Increase contractility

Answer

Increase heart rate

Answer

Decrease myocardial oxygen demand

Question 7

A patient treated for hypertension shows signs of hyperkalemia. Which class of antihypertensive agents is most likely to cause this side effect?

Accepted Answer

ACE inhibitors

Answer

Calcium channel blockers

Answer

Beta-blockers

Answer

Thiazide diuretics

Question 8

A 62-year-old patient with unstable angina is prescribed a drug to reduce myocardial oxygen demand. Which drug would be the best option?

Accepted Answer

Metoprolol

Answer

Rivaroxaban

Answer

Rosuvastatin

Answer

Captopril

Question 9

What is the primary concern regarding the dosing of statins in patients with hepatic impairment?

Accepted Answer

Increased risk of toxicity due to reduced clearance

Answer

Potential for reduced efficacy due to altered metabolism

Answer

Altered bioavailability due to first-pass metabolism

Answer

Need for mandatory dose reduction in all cases regardless of severity

Question 10

Which antihypertensive drug works by inhibiting the angiotensin-converting enzyme and reducing the production of angiotensin II?

Accepted Answer

Enalapril

Answer

Losartan

Answer

Amlodipine

Answer

Hydralazine

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?